Editorial [ Hot Topic:Recent Advances in Gastrointestinal Pharmacology: From Basic Science to Clinical Practice (Executive Editors: Gyula Mozsik and Koji Takeuchi)]

摘要

Many people of the total inhabitans suffers from the primary gastrointestinal (GI) damage with unknown etiology and secondary GI damage of which clinical feature appears in association with the presence of different physical, chemical, viral or bacterial and other noxious agents, including big numbers of drugs. In our days, a great attention has been paid to patients infected with Helicobacter pylori (H. pylori), and also to an extremely big number of patients who receive nonsteroidal anti-inflammatory drugs (NSAIDs) for treatment of thrombophylia, arteriosclerosis, stroke, myocardial heart attack or degenerative joint diseases. H. pylori produces dominantly duodenal ulcer, atrophic gastritis, dysplasia and malignancy in the stomach, meanwhile NSAIDs induce GI side effects (bleeding, ulceration, inhibition of bicarbonate secretion, changes in motility, etc). Especially, the medical indication of NSAIDs is a relatively low when considered from evidence based medicine (EBM), because their application in patients with above mentioned diseases is absolutely indicated, while this is contraindicated in patients with GI diseases. Consequently, the research is necessary in the basic and clinical fields.